These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8853897)

  • 1. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.
    Brown PH; Kim SH; Wise SC; Sabichi AL; Birrer MJ
    Cell Growth Differ; 1996 Aug; 7(8):1013-21. PubMed ID: 8853897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of a dominant-negative mutant of c-Jun.
    Brown PH; Chen TK; Birrer MJ
    Oncogene; 1994 Mar; 9(3):791-9. PubMed ID: 8108121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cFos is critical for MCF-7 breast cancer cell growth.
    Lu C; Shen Q; DuPré E; Kim H; Hilsenbeck S; Brown PH
    Oncogene; 2005 Sep; 24(43):6516-24. PubMed ID: 16027729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of oncogene-induced transformation by a deletion mutant of c-jun.
    Brown PH; Alani R; Preis LH; Szabo E; Birrer MJ
    Oncogene; 1993 Apr; 8(4):877-86. PubMed ID: 8455942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
    Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
    Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
    Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
    Kim S; Brown PH; Birrer MJ
    Oncogene; 1996 Mar; 12(5):1043-53. PubMed ID: 8649795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
    Suzukawa K; Colburn NH
    Oncogene; 2002 Mar; 21(14):2181-90. PubMed ID: 11948401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of cellular transformation by glucocorticoid receptor mutants.
    Kameda T; Iba H
    Cancer Res; 1998 Mar; 58(5):867-70. PubMed ID: 9500440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation suppressor activity of a Jun transcription factor lacking its activation domain.
    Lloyd A; Yancheva N; Wasylyk B
    Nature; 1991 Aug; 352(6336):635-8. PubMed ID: 1907719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinyl methyl ether down-regulates activator protein 1 transcriptional activation in breast cancer cells.
    Agadir A; Shealy YF; Hill DL; Zhang X
    Cancer Res; 1997 Aug; 57(16):3444-50. PubMed ID: 9270011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.
    Bossis G; Malnou CE; Farras R; Andermarcher E; Hipskind R; Rodriguez M; Schmidt D; Muller S; Jariel-Encontre I; Piechaczyk M
    Mol Cell Biol; 2005 Aug; 25(16):6964-79. PubMed ID: 16055710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE).
    Schuringa JJ; Timmer H; Luttickhuizen D; Vellenga E; Kruijer W
    Cytokine; 2001 Apr; 14(2):78-87. PubMed ID: 11356008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity.
    Hilfiker-Kleiner D; Hilfiker A; Castellazzi M; Wollert KC; Trautwein C; Schunkert H; Drexler H
    Cardiovasc Res; 2006 Jul; 71(1):108-17. PubMed ID: 16690042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of the tissue inhibitor of metalloproteinases-1 promoter in culture-activated rat hepatic stellate cells: regulation by activator protein-1 DNA binding proteins.
    Bahr MJ; Vincent KJ; Arthur MJ; Fowler AV; Smart DE; Wright MC; Clark IM; Benyon RC; Iredale JP; Mann DA
    Hepatology; 1999 Mar; 29(3):839-48. PubMed ID: 10051488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opposing functions of ATF2 and Fos-like transcription factors in c-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts.
    Daury L; Busson M; Tourkine N; Casas F; Cassar-Malek I; Wrutniak-Cabello C; Castellazzi M; Cabello G
    Oncogene; 2001 Nov; 20(55):7998-8008. PubMed ID: 11753683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rap1 reverses transcriptional repression of TGF-beta type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1.
    Fralix KD; Zhao S; Venkatasubbarao K; Freeman JW
    J Cell Physiol; 2003 Jan; 194(1):88-99. PubMed ID: 12447993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation.
    Hartl M; Bister K
    Oncogene; 1998 Dec; 17(22):2901-13. PubMed ID: 9879996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-range electrostatic interactions influence the orientation of Fos-Jun binding at AP-1 sites.
    Ramirez-Carrozzi VR; Kerppola TK
    J Mol Biol; 2001 Jan; 305(3):411-27. PubMed ID: 11152600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered AP-1/ATF complexes in adenovirus-E1-transformed cells due to EIA-dependent induction of ATF3.
    Hagmeyer BM; Duyndam MC; Angel P; de Groot RP; Verlaan M; Elfferich P; van der Eb A; Zantema A
    Oncogene; 1996 Mar; 12(5):1025-32. PubMed ID: 8649793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.